Medicinal chemistry – Page 59
-
OpinionEngineering serendipity
It takes more than random stumbling to find new reactions, says Derek Lowe
-
Business$25bn-plus trade sharpens pharma giants’ focus
Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process
-
FeatureTargeting breast cancer
Tamoxifen has been treating breast cancer for 40 years, but few would have predicted how much this drug would contribute to saving lives, writes John Mann
-
OpinionKnown unknowns
New molecules with unpredictable biological activity deserve sensible amounts of respect, says Derek Lowe
-
Business
UK to fast-track access to critical medicines
Patients could receive medicines before formal approval in exchange for monitoring data
-
-
-
BusinessRoche disputes unethical East German trial claims
Internal investigation concludes that 1980s trials were legally run and patients gave proper consent
-
-
ReviewIntroduction to biological and small molecule drug research and development
Big molecule pharma
-
BusinessJ&J puts trial data in independent hands
Yale University’s YODA seeks to help pharma avoid the dark side by acting as gatekeeper for patient records
-
NewsCroatia's vaccines manufacturer left hanging as it enters administration
Lack of government investment puts national immunology institute in crisis
-
Business
Novartis in the spotlight in mis-selling investigations
Crackdown on pharma marketing continues with US and Japanese cases
-
PodcastConotoxins
Helen Scales finds out how unique toxins found in deadly cone snail stings could herald the next generation of painkillers
-
OpinionIs there a drug for that?
Derek Lowe ponders whether anything is truly ‘undruggable’ if we look in the right places
-
NewsFlu drug stockpile may be worthless
UK committee asks government to think again on Tamiflu as its effectiveness in a pandemic is in doubt
-
OpinionThe morning after the night before
Replacing alcohol with a more benign drug sounds like a great idea, but it faces insurmountable hurdles, says Mark Peplow
-
OpinionPut the chemistry back in medicinal chemistry
Pursuing skewed priorities and easy options has impoverished the pharmaceutical industry, says David Lathbury.
-
OpinionRolling boulders uphill
Is Derek Lowe troubled by his failure to develop a compound that has made it to the pharmacy shelf?
-
Business
Regulator cracks down on 23andMe
Personal genetic profiler ordered to stop selling DNA test kits